Denali Therapeutics Inc. Common Stock
DNLIDenali Therapeutics Inc. (DNLI) is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases and other difficult-to-treat diseases of the central nervous system. Founded in 2015, Denali leverages its expertise in biology, engineering, and medicine to create innovative treatments aimed at crossing the blood-brain barrier to target underlying disease mechanisms. The company's pipeline includes investigational medicines for conditions such as Alzheimer's, Parkinson's, and ALS.
Company News
Denali Therapeutics announced publication of Phase 1/2 trial results for tividenofusp alfa (DNL310), an investigational enzyme replacement therapy for Hunter syndrome (MPS II) that crosses the blood-brain barrier. The study showed significant reduction in key disease biomarkers, normalization of heparan sulfate levels in cerebrospinal fluid and u...
Denali Therapeutics plans to raise approximately $200 million through a public offering of 9,142,857 common stock shares and pre-funded warrants at $17.50 per share, with underwriters including Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies.
Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
Denali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II). The company also has positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome type A (MPS IIIA) through the START program.
